IOTA Pharmaceuticals Limited Company accounts

COMPANY REGISTRATION NUMBER: 06279987

IOTA Pharmaceuticals Limited

Unaudited Financial Statements

30 June 2025

IOTA Pharmaceuticals Limited

Financial Statements

Year ended 30 June 2025

Contents	Page

Directors' report	1

Statement of income and retained earnings	2

Statement of financial position	3

Notes to the financial statements	4

IOTA Pharmaceuticals Limited

Directors' Report

Year ended 30 June 2025

The directors present their report and the unaudited financial statements of the company for the year ended 30 June 2025 .

Directors

The directors who served the company during the year were as follows:

D Bailey
S Boyd
P England

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

This report was approved by the board of directors on 25 August 2026 and signed on behalf of the board by:

D Bailey

Director

Registered office:

St Johns Innovation Centre

Cowley Road

Cambridge

Cambridgeshire

United Kingdom

CB4 0WS

IOTA Pharmaceuticals Limited

Statement of Income and Retained Earnings

Year ended 30 June 2025

	2025	2024
Note	£	£

Administrative expenses	1,140	11,913
Other operating income	7,350	11,000
	-------	--------
Operating profit/(loss)	6,210	( 913)

	-------	--------
Profit/(loss) before taxation	6,210	( 913)

Tax on profit/(loss)	–	–
	-------	----
Profit/(loss) for the financial year and total comprehensive income	6,210	( 913)
	-------	----

Retained losses at the start of the year	( 64,784)	( 63,871)
	--------	--------
Retained losses at the end of the year	( 58,574)	( 64,784)
	--------	--------

All the activities of the company are from continuing operations.

IOTA Pharmaceuticals Limited

Statement of Financial Position

30 June 2025

	2025	2024
Note	£	£

Current assets

Debtors	5	–	2,410
Cash at bank and in hand		14,414	15,009
		--------	--------
		14,414	17,419

Creditors: amounts falling due within one year	6	23,142	32,357
		--------	--------
Net current liabilities		8,728	14,938
		-------	--------
Total assets less current liabilities		( 8,728)	( 14,938)
		-------	--------
Net liabilities		( 8,728)	( 14,938)
		-------	--------

Capital and reserves

Called up share capital		350	350
Share premium account	7	49,496	49,496
Profit and loss account	7	( 58,574)	( 64,784)
		--------	--------
Shareholders deficit		( 8,728)	( 14,938)
		--------	--------

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

These financial statements were approved by the board of directors and authorised for issue on 25 August 2026 , and are signed on behalf of the board by:

D Bailey	P England
Director	Director

Company registration number: 06279987

IOTA Pharmaceuticals Limited

Notes to the Financial Statements

Year ended 30 June 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is St Johns Innovation Centre, Cowley Road, Cambridge, Cambridgeshire, CB4 0WS, United Kingdom.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 3 (2024: 3 ).

5. Debtors

	2025	2024
	£	£
Other debtors	–	2,410
	----	-------

6. Creditors: amounts falling due within one year

	2025	2024
	£	£
Other creditors	23,142	32,357
	--------	--------

7. Reserves

Profit and loss account - this reserve record retained earnings and accumulated losses.

8. Directors' advances, credits and guarantees

The company owed £19,278 (2024: £5,738) to its director at year end; which is included within note "Creditors: amounts falling due within one year" (Other creditors).